The 2026 regulatory landscape adds uncertainty
She told host Jenny Hamel her experience with the medication has been life changing
A 2025 trial found semaglutide resolved liver inflammation in a meaningful share of people with MASH
The program may be discontinued at any time at the sole discretion of Brightmeds LLC and/or its affiliated professional entities." This means if the FDA restricts compounded GLP-1 production, raw materials become unavailable, legal or regulatory changes occur, or the company discontinues the program for any reason, the service could end, and you would need to transition to alternative sources
The maintenance phase is not a fixed endpoint but a therapeutic plateau where your weight loss stabilizes and side effects are manageable
If youre ready to take a more natural, science-backed approach to your ulcerative colitis treatment , Dr